Dupix­ent scores speedy re­view for rhi­nos­i­nusi­tis with nasal polyps; Af­ter trans­plant, third pa­tient is HIV-free for 3 months

Re­gen­eron $REGN and Sanofi’s $SNY mon­o­clon­al an­ti­body Dupix­ent — al­ready ap­proved for eczema and asth­ma — is in line for an­oth­er ap­proval. The FDA has grant­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.